Jim Simons’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Jim Simons’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-851,300	Closed	-$495K	–	3689
2016 Q2	$495K	Buy	851,300 +264,500	+45%	+$282K	﹤0.01%	2799
2016 Q1	$857K	Buy	586,800 +447,800	+322%	+$884K	﹤0.01%	2658
2015 Q4	$445K	Buy	139,000 +111,275	+401%	+$535K	﹤0.01%	2773
2015 Q3	$173K	Buy	+27,725	New	+$259K	﹤0.01%	2923

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Simons's NWBO Position: Q3 2016 in Review

Jim Simons sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 851,300 shares — an estimated $495K sold.

Jim Simons first reported a position in NWBO in Q3 2015 and held it in 4 quarters. The position peaked at $857K in Q1 2016. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

Jim Simons reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
Jim Simons sold 851,300 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016, an estimated $495K.
Jim Simons first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2015 and held it in 4 quarters.
Jim Simons's Northwest Biotherapeutics, Inc. Common stock position peaked at $857K in Q1 2016.
54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on Renaissance Technologies's 13F filing for Q3 2016, filed 14 Nov 2016.